Development of adaptive immune effector therapies in solid tumors
Comoli, P. (Fondazione IRCCS Policlinico San Matteo (Itàlia))
Chabannon, Christian (Institut Paoli-Calmettes. Aix-Marseille University. INSERM CBT 1409. Centre for Clinical Investigation in Biotherapy)
Koehl, U. (Institute of Cellular Therapeutics. Hannover Medical School)
Lanza, Francesco (Hematology and Stem Cell Transplant. Romagna Transplant Network)
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Hudecek, Michael (University Hospital Würzburg)
Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia))
Secondino, S. (Università degli Studi di Pavia. Dipartimento di Medicina Interna e Terapia Medica)
Bonini, C. (University Vita-Salute San Raffaele)
Pedrazzoli, P. (Università degli Studi di Pavia. Dipartimento di Medicina Interna e Terapia Medica)
Universitat Autònoma de Barcelona

Fecha:	2019
Resumen:	State-of-the-art treatment strategies have drastically ameliorated the outcome of patients affected by cancer. However, resistant and recurrent solid tumors are generally nonresponsive to conventional therapies. A central factor in the sequence of events that lead to cancer is an alteration in antitumor immune surveillance, which results in failure to recognize and eliminate the transformed tumor cell. A greater understanding of the dysregulation and evasion of the immune system in the evolution and progression of cancer provides the basis for improved therapies. Targeted strategies, such as T-cell therapy, not only generally spare normal tissues, but also use alternative antineoplastic mechanisms that synergize with other therapeutics. Despite encouraging success in hematologic malignancies, adaptive cellular therapies for solid tumors face unique challenges because of the immunosuppressive tumor microenvironment, and the hurdle of T-cell trafficking within scarcely accessible tumor sites. This review provides a brief overview of current cellular therapeutic strategies for solid tumors, research carried out to increase efficacy and safety, and results from ongoing clinical trials.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article de revisió ; Article ; Versió publicada
Materia:	CAR-T ; T cells ; Checkpoint inhibitors ; Immunotherapy ; Solid tumors
Publicado en:	Annals of oncology, Vol. 30 Núm. 11 (november 2019) , p. 1740-1750, ISSN 1569-8041

DOI: 10.1093/annonc/mdz285
PMID: 31435646

11 p, 2.6 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Instituto de Investigación contra la Leucemia Josep Carreras
Artículos > Artículos publicados